Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01016444|
Recruitment Status : Unknown
Verified November 2009 by MetroHealth Medical Center.
Recruitment status was: Recruiting
First Posted : November 19, 2009
Last Update Posted : May 25, 2011
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||1250 participants|
|Official Title:||β2AR Polymorphisms and Albuterol Responsiveness in Acute Asthma|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||January 2012|
|Estimated Study Completion Date :||January 2012|
Those who respond clinically to albuterol.
Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
- B2AR polymorphisms associated with albuterol responsiveness in acute asthma. [ Time Frame: ~ 1 hour following 3 doses of albuterol Q 20 min ]
- B2AR haplotypes [ Time Frame: ~ 1hr post 3 doses of albuterol ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01016444
|Contact: Robynn Cox, RNfirstname.lastname@example.org|
|Contact: Cynthia Newnan, RNemail@example.com|
|United States, Ohio|
|MetroHealth Medical Center||Recruiting|
|Cleveland, Ohio, United States, 44109|
|Contact: Robynn Cox, RN 216-778-3227 firstname.lastname@example.org|
|Contact: Cynthia Newman, RN 216-778-3237 email@example.com|
|Principal Investigator: E. R. Mc Fadden, Jr, MD,|